Related Experiment Video
Updated: Jun 17, 2026

06:13
Enzyme-linked Immunospot Assay (ELISPOT): Quantification of Th-1 Cellular Immune Responses Against Microbial Antigens
Published on: November 23, 2010
Can ELISpot replace the tuberculin skin test for latent tuberculosis?
1Inflammatory Bowel Disease, Royal Free Hospital NHS Trust, London.
Summary
Screening for latent tuberculosis infection (LTBI) before anti-tumour necrosis factor alpha (anti-TNF-alpha) therapy is crucial. The ELISpot test shows promise for diagnosing LTBI in patients on corticosteroids, outperforming the tuberculin skin test (TST).
Area of Science:
- Immunology
- Infectious Diseases
- Rheumatology
Background:
- Screening for latent tuberculosis infection (LTBI) before anti-tumour necrosis factor alpha (anti-TNF-alpha) therapy significantly reduces active tuberculosis (TB) incidence.
- Conventional LTBI screening (clinical history, chest X-ray, tuberculin skin test [TST]) has limitations, especially in immunosuppressed patients.
Purpose of the Study:
- To evaluate the evidence quality of the interferon gamma release assay (ELISpot test) for diagnosing LTBI before anti-TNF-alpha therapy.
- To assess the agreement between ELISpot and TST in this patient population.
Main Methods:
- A systematic literature search was conducted using Ovid Medline, Embase, and the Cochrane library.
- Search terms included tuberculosis, anti-TNF-alpha agents, TST, and interferon-gamma release assay (ELISpot).
Main Results:
- ELISpot is more sensitive and specific than TST in patients on corticosteroids, avoiding cross-reactions with Bacillus Calmette-Guérin (BCG) vaccination.
- Discordance between TST and ELISpot is higher in BCG-vaccinated individuals taking corticosteroids.
- Fair agreement was observed between TST and ELISpot (72.8% agreement, kappa value=0.38).
Conclusions:
- Reactivation of LTBI post anti-TNF therapy remains a concern, though screening mitigates the risk.
- Further research is needed on the cost-effectiveness and sensitivity of ELISpot versus TST in clinical practice.
Related Concept Videos
Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
